Tagrisso 80 mg Alternative – Ositag (Osimertinib) 80 mg Tablet | Beacon Pharmaceuticals
Ositag 80 mg (Osimertinib) Tablet by Beacon Pharmaceuticals. Reference brand: Tagrisso. EGFR inhibitor; used in selected EGFR-mutated lung cancer. Prescription medicine. Brand comparison does not establish interchangeability.
Product Overview
Ositag 80 mg Tablet is listed in the supplied Beacon Pharmaceuticals anti-cancer and hematology price list. The stated active ingredient is Osimertinib. Tagrisso is a reference brand for the generic ingredient. This is a product-identification comparison, not a claim of verified bioequivalence or interchangeability.
Ositag vs Tagrisso – Reference Brand Comparison
Tagrisso is a recognized reference brand associated with Osimertinib. Ositag is listed under Beacon Pharmaceuticals. Their excipients, marketing authorizations, formulation details and regulatory evidence may differ. A clinician or pharmacist must confirm whether substitution is appropriate.
Composition and Active Ingredient
Brand: Ositag. Active ingredient: Osimertinib. Strength: 80 mg. Dosage form: Tablet. Therapeutic class: EGFR inhibitor. Listed manufacturer: Beacon Pharmaceuticals Ltd., Bangladesh. Packaging details should be confirmed on the manufacturer’s current pack.
Therapeutic Uses and Indications
Osimertinib is used in selected EGFR-mutated lung cancer. These are generic-level clinical contexts and do not independently confirm every indication for this particular branded presentation. Eligibility may depend on biomarkers, previous therapy and country-specific labeling.
Mechanism of Action – How Osimertinib Works
Osimertinib blocks susceptible mutant EGFR. This mechanism alone does not establish suitability or effectiveness for an individual patient.
Dosage and Administration
The 80 mg shown is the strength of this tablet, not a recommended daily dose. Dose, timing, food instructions and treatment duration must be determined by the treating specialist using the current authorized prescribing information. Do not change dose or substitute brands or strengths without medical approval.
Contraindications
Contraindications depend on Osimertinib, formulation and individual medical conditions. Review the current official prescribing information, particularly hypersensitivity, pregnancy-related and organ-function restrictions.
Warnings and Precautions
Important safety considerations include lung inflammation and cardiac effects. The prescriber may require laboratory testing, cardiac or organ-function assessment, and ongoing monitoring.
Possible Side Effects
Potential adverse effects and serious reactions include lung inflammation and cardiac effects. Other reactions can occur. Consult the product leaflet for the full adverse-effect profile and seek medical care for severe symptoms.
Drug Interactions
Drug interactions may affect treatment effectiveness or toxicity. Inform the treating clinician of all prescriptions, over-the-counter products, herbal supplements and other treatments.
Pregnancy, Fertility and Breastfeeding
Some oncology and hematology medicines can cause fetal harm and require specific contraception or breastfeeding restrictions. Follow the medicine-specific official labeling and specialist advice.
Storage and Handling
Store according to the instructions printed on the actual Beacon Pharmaceuticals pack. Protect from inappropriate heat, humidity and light, and keep out of reach of children. Do not assume the storage conditions of another brand apply.
Why Is Ositag Listed as an Alternative to Tagrisso?
The comparison helps identify another listed brand containing Osimertinib. It does not establish identical formulation, regulatory approval, bioequivalence or permission to substitute.
Manufacturer Information
Listed brand: Ositag. Manufacturer: Beacon Pharmaceuticals Ltd., Bangladesh. Reference brand: Tagrisso. Generic: Osimertinib. Strength: 80 mg. Dosage form: Tablet.
Frequently Asked Questions
What is Ositag 80 mg? It is a tablet containing Osimertinib 80 mg according to the supplied Beacon price list. What is it used for? Osimertinib is used in selected EGFR-mutated lung cancer, subject to specialist assessment. Can it replace Tagrisso? Not automatically; a qualified professional must check product-specific equivalence and regulatory requirements. Is a prescription required? Yes, appropriate prescription and specialist supervision are necessary.
Important Medical Disclaimer
This listing is for educational pharmaceutical identification only and is not a substitute for medical advice, official product labeling or regulatory review. Brand, strength and pack details should be confirmed against the current manufacturer information before dispensing.
| Generic Name | Osimertinib |
|---|---|
| Strength | 80 mg |
| Manufacturer | Beacon Pharmaceuticals Ltd. |
Related products
Alunbrig 180 mg Alternative – Brigacent (Brigatinib) 180 mg Tablet | Incepta Pharmaceuticals
Brigacent 180 mg (Brigatinib) Tablet is listed in the supplied Lucent price catalogue attributed to Incepta Pharmaceuticals Ltd. Reference brand: Alunbrig (Takeda).
Pack: 7 tablets. Prescription medicine. Verify the exact manufacturer label and regulatory status; reference-brand comparison does not establish interchangeability.
Gilotrif 40 mg Alternative – Afatin (Afatinib) 40 mg Tablet | Beacon Pharmaceuticals
Iressa 250 mg Alternative – Geficent (Gefitinib) 250 mg Tablet | Incepta Pharmaceuticals
Geficent 250 mg (Gefitinib) Tablet is listed in the supplied Lucent price catalogue attributed to Incepta Pharmaceuticals Ltd. Reference brand: Iressa (AstraZeneca).
Pack: 10 tablets. Prescription medicine. Verify the exact manufacturer label and regulatory status; reference-brand comparison does not establish interchangeability.
Tarceva 100 mg Alternative – Erlocent (Erlotinib) 100 mg Tablet | Incepta Pharmaceuticals
Erlocent 100 mg (Erlotinib) Tablet is listed in the supplied Lucent price catalogue attributed to Incepta Pharmaceuticals Ltd. Reference brand: Tarceva (Roche / Genentech).
Pack: 10 tablets. Prescription medicine. Verify the exact manufacturer label and regulatory status; reference-brand comparison does not establish interchangeability.
Tarceva 150 mg Alternative – Erlonix (Erlotinib) 150 mg Tablet | Beacon Pharmaceuticals
Vizimpro 45 mg Alternative – Dacocent (Dacomitinib) 45 mg Tablet | Incepta Pharmaceuticals
Xalkori 250 mg Alternative – Alkriz (Crizotinib) 250 mg Tablet | Beacon Pharmaceuticals
Xalkori 250 mg Alternative – Crizocent (Crizotinib) 250 mg Capsule | Incepta Pharmaceuticals
Crizocent 250 mg (Crizotinib) Capsule is listed in the supplied Lucent price catalogue attributed to Incepta Pharmaceuticals Ltd. Reference brand: Xalkori (Pfizer).
Pack: 12 capsules. Prescription medicine. Verify the exact manufacturer label and regulatory status; reference-brand comparison does not establish interchangeability.

Reviews
There are no reviews yet.